Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948744 | 0.69 | ALDH1A1 (0.40) | ALDH1A1HPGD | |
| SCHEMBL954765 | 0.68 | ALDH1A1 (0.42) | ALDH1A1HPGD | |
| SCHEMBL20862007 | 0.68 | EPHX1 (0.30) | — | |
| SCHEMBL30601232 | 0.68 | ALDH1A1 (0.39) | ALDH1A1HPGD | |
| SCHEMBL1945874 | 0.67 | ALDH1A1 (0.56) | ALDH1A1HPGD | |
| SCHEMBL29809738 | 0.67 | ALDH1A1 (0.56) | ALDH1A1HPGD | |
| SCHEMBL198463 | 0.66 | IDO1 (0.52) | ALDH1A1 | |
| SCHEMBL7779906 | 0.66 | ALDH1A1 (0.43) | ALDH1A1HPGD | |
| SCHEMBL1023433 | 0.65 | PTGDR2 (0.40) | ALDH1A1HPGD | |
| SCHEMBL9080677 | 0.64 | ALDH1A1 (0.40) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | ALDH1A1 2492/4885HPGD 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.